COVID-19: time to flatten the infodemic curve

Tentolouris, Anastasios; Ntanasis‐Stathopoulos, Ioannis; Vlachakis, Panayotis K.; Tsilimigras, Diamantis I.; Gavriatopoulou, Maria; Dimopoulos, Meletios A.

doi:10.1007/s10238-020-00680-x

Cited by 32 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical spectrum ranges from mild symptoms to a severe and life-threatening disease course in up to 5-10% of patients [3]. The urgent need to achieve herd immunity has made vaccine development a global priority [5,6] and led to accelerated vaccine development in less than a year [5,7]. Significant efficacy has been demonstrated for different vaccine types in several phase 3 placebo-controlled, randomized trials (RCTs).…”

Section: Introductionmentioning

confidence: 99%

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Terpos

Gavriatopoulou

Fotiou

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and 50. One hundred and thirty-two patients with CLL/lymphomas and 214 healthy matched controls vaccinated during the same period, at the same center were enrolled in the study (NCT04743388). Vaccination with two doses of the BNT162b2 vaccine led to lower production of NAbs against SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Disease-related immune dysregulation and therapy-related immunosuppression are involved in the low humoral response. Importantly, active treatment with Rituximab, Bruton’s tyrosine kinase inhibitors, or chemotherapy was an independent prognostic factor for suboptimal antibody response. Patients with HL showed superior humoral responses to the NHL/CLL subgroups. In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures.

show abstract

Section: Introductionmentioning

confidence: 99%

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Terpos

Gavriatopoulou

Fotiou

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is unclear whether the vaccine can induce the development of anti-PF4 antibodies (seroconversion) in vaccinated individuals who have not developed thrombosis [ 17 ], since the data published so far are limited to patients with overt thrombotic complications. Determining the indications of anti-PF4 antibody testing in vaccine recipients is essential for assuring best clinical practice and for avoiding misinformation [ 17 , 18 ]. In this context, the aim of this prospective study was to assess the presence of antibodies against heparin/PF4 in healthy adults who received the first dose of the ChAdOx1 nCov-19 vaccine, according to the national vaccination program, and correlate them with clinical data and antibody responses to the vaccine.…”

Section: Introductionmentioning

confidence: 99%

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

Terpos

Politou

Ntanasis‐Stathopoulos

et al. 2021

Vaccines

Self Cite

View full text Add to dashboard Cite

It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis. The aim of this prospective study was to evaluate the presence of antibodies against heparin/PF4 in adults who received a first dose of the ChAdOx1 nCov-19 vaccine, and correlate them with clinical data and antibody responses to the vaccine. We detected non-platelet activating anti-PF4 antibodies in 67% (29/43) of the vaccinated individuals on day 22 following the first dose of the ChAdOx1 nCov-19 vaccine, though these were detected in low titers. Furthermore, there was no correlation between the presence of anti-PF4 IgG antibodies and the baseline clinical characteristics of the patients. Our findings suggest that the ChAdOx1 nCov-19 vaccine can elicit anti-PF4 antibody production even in recipients without a clinical manifestation of thrombosis. The presence of anti-PF4 antibodies was not sufficient to provoke clinically evident thrombosis. Our results offer an important insight into the ongoing investigations regarding the underlying multifactorial pathophysiology of thrombotic events induced by the ChAdOx1 nCov-19 vaccine.

show abstract

“…During this time of uncertainty, health care professionals also need strategies to separate what is accurate, what is inaccurate, and the in-between information. Pharmacists can use the following strategies provided by the WHO for themselves as well as patients 108 :…”

Section: Navigating the Infodemic Eramentioning

confidence: 99%

Coronavirus disease 2019: A comprehensive review on recent clinical updates and management tools for pharmacists

Bhargab

Dash²,

Newar

et al. 2021

PBJ

View full text Add to dashboard Cite

In the Hubei region of China, a pneumonia outbreak occurred in December 2019, which was confirmed to be caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It quickly became known as Coronavirus Disease 2019 or simply COVID-19, a pandemic that continues to devastate countries across the world. Through this COVID-19 pandemic, pharmacists across the globe have continued to offer direct patient care and provided frontline service to society. However, while the frontline staff is heralded, they are relegated to the background and overlooked most of the time. The most reachable healthcare providers are pharmacists because they can provide direct medical services despite tight regulations and restrictions related to the pandemic. During this pandemic, the involvement of pharmacists to handle COVID-19 and its complications proved to be crucial in alleviating the burden on the already strained healthcare system. They have provided very important services such as distributing medications to patients, encouraging adherence to medications for better control of chronic diseases, consulting on minor illnesses, clarifying myths regarding COVID-19, and contributing to COVID-19 screening. The treatment or management of COVID-19 was based on initial findings but is now being updated several times based on viral mutation, different studies across the globe, etc. This review focuses on recent clinical updates and tools that would help pharmacists with a more systematic approach to properly handling COVID-19 and its complications.

show abstract

COVID-19: time to flatten the infodemic curve

Cited by 32 publications

References 26 publications

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

Coronavirus disease 2019: A comprehensive review on recent clinical updates and management tools for pharmacists

Contact Info

Product

Resources

About